IP Library Granted Patent US 10,928,397
Granted Patent B2
US 10,928,397 · App. 16/130,616 · Granted Feb 23, 2021

Methods involving Mena

Inventors: Frank B. Gertler (Boston, MA); Shannon K. Hughes (Cambridge, MA); Douglas A. Lauffenburger (Cambridge, MA); Jason Neil (Jamaica Plain, MA); Forest White (Sutton, MA); John S. Condeelis (Bronx, NY); Madeleine J. Oudin (Cambridge, MA)
Assignees: Massachusetts Institute of Technology; Albert Einstein College of Medicine
G01N33/57492C07K14/435C07K16/18C12N15/113C12Q1/42G01N33/5011G01N33/6872C12N2310/122C12N2310/14C12N2320/30G01N2333/71G01N2333/916G01N2500/04G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,928,397
App. No.
16/130,616
Granted
Feb 23, 2021
Kind
B2
Abstract

Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on Mena INV .

Claims (14)

1. A method of identifying an agent as an inhibitor of sarcoma or carcinoma cell invasion or as an inhibitor of metastasis of a carcinoma or sarcoma, comprising contacting a preparation comprising a protein-tyrosine phosphatase 1b (PTP1b)-interacting growth factor receptor and a PTP1b in the presence of an amount of Mena INV and an amount of Mena and quantifying the association of the PTP1b-interacting growth factor receptor and PTP1b in the presence of the agent and in the absence of the agent, wherein an agent that increases the association of PTP1b-interacting growth factor receptor and PTP1b in the presence of the agent as compared to in the absence of the agent is identified as an inhibitor of sarcoma or carcinoma cell invasion or of metastasis, and an agent that does not increase, or decreases, the association of PTP1b-interacting growth factor receptor and PTP1b in the presence of the agent as compared to in the absence of the agent is not identified as an inhibitor of sarcoma or carcinoma cell invasion or metastasis.

2. The method of claim 1 , wherein the PTP1b-interacting growth factor receptor is an epithelial growth factor receptor (EGFR).

3. The method of claim 1 , wherein the PTP1b-interacting growth factor receptor is a hepatoctye growth factor receptor (HGFR or MET).

4. The method of claim 1 , wherein the PTP1b-interacting growth factor receptor is a receptor for IGF, AXL, HB-EGF, AREG or NRG.

5. The method of claim 1 , wherein the PTP1b-interacting growth factor receptor is expressed by a tumor cell or on a tumor cell line.

6. The method of claim 1 , wherein the Mena INV is expressed by a tumor cell or by a cell of a tumor cell line.

7. The method of claim 1 , wherein a cell of the carcinoma expresses Mena INV .

8. The method of claim 1 , wherein the association of PTP1b and the PTP1b-interacting growth factor receptor is quantified using a proximity ligation association assay.

9. The method of claim 1 , comprising stimulating the PTP1b-interacting growth factor receptor.

10. The method of claim 1 , wherein the Mena INV is a human Mena INV .

11. The method of claim 1 , wherein the Mena is a human Mena.

12. The method of claim 1 , wherein the agent is a small organic molecule of 2000 daltons or less, an antibody, an antibody fragment, a fusion protein or peptide, an RNAi agent or an aptamer.

13. The method of claim 1 , wherein the agent is an RNAi agent and is an siRNA or a shRNA.

14. The method of claim 1 , wherein the carcinoma is a mammary carcinoma.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →